ANIP
ANI Pharmaceuticals Inc

1,122
Mkt Cap
$1.96B
Volume
710,592.00
52W High
$99.50
52W Low
$52.50
PE Ratio
-117.64
ANIP Fundamentals
Price
$90.43
Prev Close
$90.23
Open
$83.21
50D MA
$93.58
Beta
0.77
Avg. Volume
331,935.61
EPS (Annual)
-$1.04
P/B
4.50
Rev/Employee
$684,923.08
Loading...
Loading...
News
all
press releases
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance
ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance. The company provided EPS guidance of 7.370-7.640 for the period, compared to the consensus estimate of 6.730. The company also...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
Zacks·21h ago
News Placeholder
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
Zacks·23h ago
News Placeholder
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Zacks·24h ago
News Placeholder
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Zacks·24h ago
News Placeholder
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
Zacks·24h ago
News Placeholder
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Zacks·1d ago
News Placeholder
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
Zacks·1d ago
News Placeholder
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1d ago
News Placeholder
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago

Latest ANIP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.